[1] Chalasani NP, Maddur H, Russo MW, et al. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol, 2021, 116:878-898.
[2] Chalasani NP, Hayashi PH, Bonkovsky HL, et al.ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol,2014, 109:950-966.
[3] Danan G, Bénichou C. Causality assessment of adverse reactions to drugs--Ⅰ. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol, 1993, 46: 1323-1330.
[4] Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs--Ⅱ. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol, 1993, 46: 1331-1336.
[5] Ghabril M, Gu J, Yoder L, et al. Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury. Gastroenterology, 2019, 157:1245–1252.e3.
[6] Danan G, Teschke R. RUCAM in drug and herb induced liver injury: The update. Int J Mol Sci, 2016, 17: 14-46.
[7] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 中华肝脏病杂志, 2015, 23: 810-827.
[8] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol, 2019,70: 1222-1261. |
